

Fredric N. Eshelman Pharm.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 24, 2017 2:48 AM ET
Pharmaceuticals

Company Overview of Innocrin Pharmaceuticals Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Fredric N. Eshelman Pharm.D.Chief Executive Officer and Director, Innocrin Pharmaceuticals Inc.AgeTotal Calculated CompensationThis person is connected to 10 Board Members in 10 different organizations across 11 different industries.See Board Relationships68--
Background

		Dr. Fredric N. Eshelman, also known as Fred, Pharm.D., has been the Chief Executive Officer of Innocrin Pharmaceuticals Inc. since March 15, 2017.  Dr. Eshelman is the Founder and Principal of Eshelman Ventures, LLC. Dr. Eshelman served as the Chief Executive Officer and Executive Chairman of Pharmaceutical Product Development Inc. from July 1, 1990 to July 2009. He served as an Executive Chairman of Furiex Pharmaceutical Inc. Dr. Eshelman founded Pharmaceutical Product ... Development Inc.'s predecessor and served as the Chief Executive Officer until 1989. He served as the Senior Vice President, Development of Glaxo Inc. and held various roles in drug development with other pharmaceutical companies such as Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. He has been the Non-Executive Chairman of The Medicines Company since August 31, 2015. He has been the Founding Chairman of Furiex Pharmaceuticals, Inc. since 2009 and has been its Director since October 2009. He served as Vice Chairman of Pharmaceutical Product Development from July 1993 to July 2009 and its Director since July 1990. He has been an Independent Director of Valeant Pharmaceuticals International, Inc. since March 8, 2016. He serves as the Director at Asepticys, Inc. He has been a Director of G1 Therapeutics Inc. since February 5, 2015 and Innocrin Pharmaceuticals Inc. since April 15, 2015. He serves on a number of industry boards, including the Association of Clinical Research Organizations. He is a Member of Advisory Board of Auven Therapeutics Management L.L.L.P and Princeton Biopharma Capital Partners LLC. Most recently, he was appointed Chairman of The Medicine's Company. Dr. Eshelman serves as a Director of Meryx Inc., He serves on the Board of visitors for the School of Pharmacy at the University of North Carolina. In addition, he chairs the board of visitors for the School of Pharmacy at UNC-CH. He served as a Director of Spotlight Health, Inc. and Takeda California, Inc. Dr. Eshelman served as a Director of Glaxo Inc. from 1989 to 1990 and served as a Director of Accelerator Corporation and Takeda San Diego, Inc. Dr. Eshelman served as a Director of PrimeCyte Inc. and Aton Pharma, Inc. He was on the Board of Trustees for UNC-W and in 2011 was appointed by the NC General Assembly to serve on the Board of Governors for the state’s multi-campus university system as well as the NC Biotechnology Center. He has received many awards including the Davie and Distinguished Service Awards from UNC, NC Entrepreneur Hall of Fame Award and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy. He has a Doctorate of Pharmacy from the University of Cincinnati and a BS in Pharmacy from the University of North Carolina at Chapel Hill in 1972 and a Graduate of the Owner President Management program at Harvard Business School.Read Full Background




Corporate Headquarters
4505 Emperor BoulevardDurham, North Carolina 27703United StatesPhone: 919-467-8539Fax: 919-467-8540
Board Members Memberships
DirectorMeryx Inc.DirectorAsepticys, Inc.2009-PresentFounding ChairmanFuriex Pharmaceuticals, Inc.2015-PresentNon-Executive ChairmanThe Medicines Company2015-PresentDirectorG1 Therapeutics, Inc.2015-PresentChief Executive Officer and DirectorInnocrin Pharmaceuticals Inc.2016-PresentIndependent DirectorValeant Pharmaceuticals International, Inc.
Education
BS 1972University Of North Carolina At Chapel HillDoctorate University of Cincinnati
Other Affiliations
The Medicines CompanyPharmaceutical Product Development, LLCTakeda California, Inc.Spotlight Health, Inc.Valeant Pharmaceuticals International, Inc.University Of North Carolina At Chapel HillPrimeCyte Inc.Aton Pharma, Inc.University of CincinnatiAccelerator CorporationAbCRO, Inc.Auven Therapeutics Management L.L.L.PFuriex Pharmaceuticals, Inc.G1 Therapeutics, Inc.Princeton Biopharma Capital Partners, LLCMeryx Inc.Eshelman Ventures, LLCAsepticys, Inc.


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Innocrin Pharmaceuticals Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Equilar Atlas SEO | Page Not Available (404)












 
















Log in | Sign up













PAGE NOT AVAILABLE


Please click here to continue.













				Browse individual profiles:
				
					 A
				
					 B
				
					 C
				
					 D
				
					 E
				
					 F
				
					 G
				
					 H
				
					 I
				
					 J
				
					 K
				
					 L
				
					 M
				
					 N
				
					 O
				
					 P
				
					 Q
				
					 R
				
					 S
				
					 T
				
					 U
				
					 V
				
					 W
				
					 X
				
					 Y
				
					 Z



			� 2017 Equilar, Inc.  | 
			About
			 | 
			Terms of Use
			 | 
			Executive Rankings














 




FREDRIC N  ESHELMAN - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











FREDRIC N  ESHELMAN
Check out list of companies and businesses related to FREDRIC N  ESHELMAN. Find out FREDRIC N  ESHELMAN address and contact details. View other people related to FREDRIC N  ESHELMAN - coworkers, colleagues, companions, etc.
Address:   

6814 TOWLES ROAD  WILMINGTON 28409 NC




Companies related to FREDRIC N  ESHELMAN
CIKCompany NamePositionCompany Address0000885590Valeant Pharmaceuticals International, Inc.Director 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC H7L 4A80001003124PHARMACEUTICAL PRODUCT DEVELOPMENT INCCEO 929 NORTH FRONT STREET  WILMINGTON 284010001113481MEDICINES CO /DEDirector 8 SYLVAN WAY  PARSIPPANY 070540001560241G1 Therapeutics, Inc.Director 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK 27709




FREDRIC N  ESHELMAN on the Web
Persons related to FREDRIC N  ESHELMAN - Valeant Pharmaceuticals International, Inc.NamePositionCityCHRISTINA  ACKERMANNEVP AND GENERAL COUNSEL BRIDGEWATERWILLIAM A  ACKMANNEW YORKTHOMAS  APPIOEVP, COMPANY GROUP CHAIRMAN BRIDGEWATERRobert Roswell  Chai-OnnEVP, CLO, General Counsel MISSISSAUGARobert Roswell  Chai-OnnEVP, GC & Corp. Sec. MISSISSAUGARobert Roswell  Chai-OnnEVP, Gen. Couns. and Corp. Sec MONTREALRobert Roswell  Chai-OnnMONTREALRobert Roswell  Chai-OnnEVP, Gen. Couns. & Corp. Sec. MONTREALRobert Roswell  Chai-OnnMONTREALRobert Roswell  Chai-OnnEVP, Gen. Couns. & Corp. Sec. LAVALRobert Roswell  Chai-OnnEVP, Gen. Couns. & Corp. Secy. LAVALMichel  ChouinardMISSISSAUGAMichel  ChouinardCOO, Biovail Labs. Intl SRL MISSISSAUGAMichel  ChouinardCOO, Biovail Labs.Int'l SRL WORTHING, CHRIST CHURCHMichel  ChouinardCOO, Biovail Labs. Intl SRL MISSISSAUGAMichel  ChouinardCOO, Biovail Labs. Intl SRL MISSISSAUGASCHUTTER RICHARD U  DEDirector PALO ALTOSILVA RAJIV  DEPresident & COO MISSISSAUGASILVA RAJIV  DEPresident & COO, Spec. Pharma. MISSISSAUGASILVA RAJIV  DEPresident,VPII&COO,Spec.Pharma MISSISSAUGASILVA RAJIV  DEPresident & COO MISSISSAUGASILVA RAJIV  DEPresident and COO MONTREALSILVA RAJIV  DEPresident & COO MONTREALMark Andrew  DurhamSenior VP, HR & Shared Svs MISSISSAUGAMark Andrew  DurhamSVP, HR & Shared Services MISSISSAUGAMark Andrew  DurhamSVP, HR & Shared Services MISSISSAUGAMark Andrew  DurhamSVP, Human Resources MISSISSAUGAMark Andrew  DurhamSVP Human Resources MISSISSAUGASam  EldessoukySVP, CHIEF ACCOUNTING OFFICER PRINCETONFREDRIC N  ESHELMANDirector WILMINGTONRonald Harold  FarmerDirector MISSISSAUGARonald Harold  FarmerDirector MONTREALRonald Harold  FarmerDirector LAVALHans Christian  FibigerMISSISSAUGAHans Christian  FibigerChief Scientific Officer MISSISSAUGAHans Christian  FibigerChief Scientific Officer MISSISSAUGAHans Christian  FibigerChief Scientific Officer MISSISSAUGAHans Christian  FibigerChief Scientific Officer MISSISSAUGAStephen  FraidinNEW YORKGilbert  GodinExecutive Vice-President & COO MISSISSAUGAGilbert  GodinEVP & COO MISSISSAUGAGilbert  GodinEVP & COO MISSISSAUGACOLLEEN A  GOGGINSDirector NEW BRUNSWICKCOLLEEN A  GOGGINSDirector BRIDGEWATERSERGE  GOUINMISSISSAUGASERGE  GOUINDirector MISSISSAUGAGregory David  GubitzMISSISSAUGAGregory David  GubitzSenior Vice President & GC MISSISSAUGAGregory David  GubitzSVP, Corp. Devel. & GC MISSISSAUGADavid Robert  HaleDirector SAN FRANCISCOSusan  HallGlobal Head of R&D MISSISSAUGASusan  HallGlobal Head of R&D MONTREALSusan  HallGlobal Head of R&D MONTREALSusan  HallGlobal Head of R&D LAVALJason David  HansonEVP, Company Group Chairman MONTREALFred  HassanDirector LAVALPaul  HerendeenEVP and CFO ROCKAWAYWilliam D.  HumphriesEVP, Company Group Chairman ALPHARETTAROBERT A  INGRAMDirector ROBERT ALEXANDER  INGRAMDirector MISSISSAUGAROBERT ALEXANDER  INGRAMDirector MISSISSAUGAROBERT ALEXANDER  INGRAMDirector MISSISSAUGAROBERT ALEXANDER  INGRAMDirector MONTREALROBERT ALEXANDER  INGRAMDirector LAVALDEBORA  JORNEVP, Company Group Chairman BRIDGEWATERARGERIS N  KARABELASDirector SAN DIEGOSARAH B  KAVANAGHDirector LAVALAri  KellenEVP, Company Group Chairman BRIDGEWATERAri  KellenEVP, Company Group Chairman BRIDGEWATERAri  KellenEVP, Company Group Chairman BRIDGEWATERLaizer  KornwasserEVP, Company Group Chairman FRANKLIN LAKESLaizer  KornwasserEVP, Company Group Chairman MONTREALLaizer  KornwasserEVP, Company Group Chairman LAVALLaizer  KornwasserEVP, Company Group Chairman BRIDGEWATERLaizer  KornwasserBRIDGEWATERLaizer  KornwasserEVP, Company Group Chairman BRIDGEWATERLaizer  KornwasserEVP, Company Group Chairman BRIDGEWATERDavid H.  LaidleyDirector MISSISSAUGADavid H.  LaidleyDirector MISSISSAUGAJohn Spencer  LanthierMISSISSAUGAJohn Spencer  LanthierDirector MISSISSAUGAPhilip Walden  Loberg JrEVP, Interim CFO MISSISSAUGAPhilip Walden  Loberg JrEVP, Interim CFO MISSISSAUGAANDERS  LONNERDirector ALISO VIEJOANDERS  LONNERDirector BRIDGEWATERRichard Kevin  MastersonPres.&COO,Valeant Int(BB)SRL MISSISSAUGARichard Kevin  MastersonPres. & COO, Valeant Int. (BB) MISSISSAUGARichard Kevin  MastersonPres. & COO, Valeant Intl. BB MONTREALChristine  MayerSVP, BTA Pharmaceuticals, Inc. MISSISSAUGAChristine  MayerSVP, BTA Pharmaceuticals, Inc. MISSISSAUGAChristine  MayerSVP, BTA Pharmaceuticals, Inc. MISSISSAUGAKYRIAZI THEO  MELASDirector KYRIAZI THEO  MELASDirector MISSISSAUGAKYRIAZI THEO  MELASDirector MISSISSAUGAKYRIAZI THEO  MELASDirector MONTREALKYRIAZI THEO  MELASDirector LAVALPavel  MirovskyEVP, Pres. & GM Valeant EMENA LAVALG Mason  MorfitDirector SAN FRANCISCOMargaret Jean  MulliganMISSISSAUGAMargaret Jean  MulliganSVP & CFO MISSISSAUGAMargaret Jean  MulliganEVP, CFO MISSISSAUGAJOSEPH C  PAPACHAIRMAN & CEO CORONAMARK W  PARRISHDirector MISSISSAUGAMARK W  PARRISHDirector MISSISSAUGALAURENCE E  PAULDirector MISSISSAUGALAURENCE E  PAULDirector MISSISSAUGALAURENCE E  PAULDirector MISSISSAUGALAURENCE E  PAULDirector MISSISSAUGALAURENCE E  PAULDirector MISSISSAUGALAURENCE E  PAULDirector MONTREALJohn  PaulsonDirector NEW YORKJ. Michael  PearsonChief Executive Officer ALISO VIEJOJ. Michael  PearsonMISSISSAUGAJ. Michael  PearsonChief Executive Officer MISSISSAUGAJ. Michael  PearsonChief Executive Officer MISSISSAUGAJ. Michael  PearsonChief Executive Officer MISSISSAUGAJ. Michael  PearsonChief Executive Officer MONTREALJ. Michael  PearsonMONTREALJ. Michael  PearsonChief Executive Officer LAVALPershing Square Capital Management, L.P.Director NEW YORKFrank  PotterMISSISSAUGAFrank  PotterDirector MISSISSAUGAROBERT N  POWERDirector MADISONROBERT N  POWERMISSISSAUGAROBERT N  POWERDirector MISSISSAUGAROBERT N  POWERDirector MISSISSAUGAROBERT N  POWERDirector MONTREALROBERT N  POWERDirector LAVALROBERT N  POWERMONTREALNorma Ann  ProvencioDirector COVINANorma Ann  ProvencioDirector MISSISSAUGANorma Ann  ProvencioDirector MISSISSAUGANorma Ann  ProvencioDirector MISSISSAUGANorma Ann  ProvencioDirector MONTREALNorma Ann  ProvencioDirector LAVALPS Management GP, LLCNEW YORKRUSSEL C  ROBERTSONDirector BRIDGEWATERRobert L.  RosielloEVP, Corp Dev & Strategy BRIDGEWATERThomas W. Sr.  RossDirector BRIDGEWATERHoward Bradley  SchillerChairman and CEO MISSISSAUGAHoward Bradley  SchillerEVP and CFO MISSISSAUGAHoward Bradley  SchillerEVP and CFO MONTREALHoward Bradley  SchillerEVP and CFO MONTREALHoward Bradley  SchillerEVP and CFO LAVALHoward Bradley  SchillerChief Financial Officer LAVALLloyd Mitchell  SegalMISSISSAUGALloyd Mitchell  SegalDirector MISSISSAUGALloyd Mitchell  SegalDirector MISSISSAUGALloyd Mitchell  SegalDirector MISSISSAUGALloyd Mitchell  SegalDirector MONTREALLloyd Mitchell  SegalDirector LAVALDouglas John Paul  SquiresMISSISSAUGADouglas John Paul  SquiresDirector MISSISSAUGAKATHARINE BERGHUIS  STEVENSONDirector BRAMPTONKATHARINE BERGHUIS  STEVENSONDirector MONTREALKATHARINE BERGHUIS  STEVENSONDirector LAVALKATHARINE BERGHUIS  STEVENSONDirector LAVALKATHARINE BERGHUIS  STEVENSONDirector LAVALKATHARINE BERGHUIS  STEVENSONDirector MISSISSAUGAKATHARINE BERGHUIS  STEVENSONDirector MISSISSAUGAKATHARINE BERGHUIS  STEVENSONDirector MISSISSAUGABrian M.  StolzEVP, Administration & CHCO MISSISSAUGABrian M.  StolzEVP, Administration and CHCO MISSISSAUGABrian M.  StolzEVP, Administration and CHCO MONTREALBrian M.  StolzEVP Administration & CHCO MONTREALBrian M.  StolzEVP, Administration and CHCO MONTREALBrian M.  StolzEVP, Administration and CHCO LAVALLouis Randall  TullMISSISSAUGALouis Randall  TullDirector MISSISSAUGAJEFFREY W  UBBENDirector JEFFREY W  UBBENDirector SAN FRANCISCOVA Partners I, LLCSAN FRANCISCOVA Partners I, LLCSAN FRANCISCOValueAct Capital Management, L.P.SAN FRANCISCOValueAct Capital Management, L.P.SAN FRANCISCOValueAct Capital Management, LLCSAN FRANCISCOValueAct Capital Management, LLCSAN FRANCISCOValueAct Capital Master Fund, L.P.SAN FRANCISCOValueAct Capital Master Fund, L.P.SAN FRANCISCOValueAct Co-Invest Master Fund, L.P.SAN FRANCISCOValueAct Co-Invest Master Fund, L.P.SAN FRANCISCOValueAct Holdings GP, LLCSAN FRANCISCOValueAct Holdings GP, LLCSAN FRANCISCOValueAct Holdings, L.P.Director SAN FRANCISCOValueAct Holdings, L.P.Director SAN FRANCISCOEvery Michael Robert  VanMISSISSAUGAEvery Michael Robert  VanDirector MISSISSAUGAEvery Michael Robert  VanDirector MISSISSAUGAEvery Michael Robert  VanDirector MISSISSAUGAAMY B  WECHSLERDirector BRIDGEWATERDaniel Mark  WechslerEVO, Co. Grp. Chmn, Eye Health LAVALRyan  WeldonEVP, Company Group Chairman MONTREALRyan  WeldonEVP, Company Group Chairman LAVALRyan  WeldonEVP, Company Group Chairman LAVALWilliam McDowall  WellsChief Executive Officer MISSISSAUGAWilliam McDowall  WellsChief Executive Officer MISSISSAUGAWilliam McDowall  WellsDirector MISSISSAUGAWilliam McDowall  WellsDirector MISSISSAUGAAnne Clem  WhitakerEVP, Company Group Chairman DURHAMPersons related to FREDRIC N  ESHELMAN - PHARMACEUTICAL PRODUCT DEVELOPMENT INCNamePositionCityLee  BabissExec. VP--Global Lab Services WILMINGTONLINDA  BADDOURChief Financial Officer WILMINGTONLINDA  BADDOURChief Financial Officer WILMINGTONLINDA  BADDOURFormer Chief Financial Officer WILMINGTONSTUART  BONDURANTDirector CHAPEL HILLVAUGHN D  BRYSONDirector WILMINGTONFrancis J  CasieriSr. VP, Global Business Dev. WILMINGTONPAUL  COLVINEVP--Clinical Development WILMINGTONPAUL S  COVINGTONExecutive Vice President WILMINGTONDaniel G  DarazsdiChief Financial Officer WILMINGTONDaniel G  DarazsdiWILMINGTONFRED B  DAVENPORT JRPresident WILMINGTONChristine A  DingivanEVP/Chief Medical Officer WILMINGTONChristine A  DingivanWILMINGTONFREDRIC N  ESHELMANCEO WILMINGTONFREDRIC N  ESHELMANExecutive Chairman WILMINGTONMARYE ANNE  FOXDirector RALEIGHMARYE ANNE  FOXDirector LA JOLLAFRED  FRANKDirector NEW YORKDAVID L  GRANGEDirector WHEATONDAVID L  GRANGEChief Executive Officer WILMINGTONJUDD  HARTMANGeneral Counsel WILMINGTONJUDD  HARTMANGeneral Counsel WILMINGTONRaymond H  HillChief Executive Officer WILMINGTONRaymond H  HillChief Executive Officer WILMINGTONROBERT ALEXANDER  INGRAMDirector WILMINGTONCATHY  KLEMADirector NEW YORKCATHY  KLEMADirector NEW YORKTERRY  MAGNUSONDirector CHAPEL HILLERNEST  MARIODirector PALO ALTOERNEST  MARIODirector PRINCETONJOHN A  MCNEILL JRDirector WHITEVILLEWilliam W  RichardsonSr. VP Global Bus. Development RALEIGHWilliam W  RichardsonSr. VP Global Bus. Development WILMINGTONCOLIN  SHANNONNEW MARKETCOLIN  SHANNONEVP, Global Clinical Ops. NEW MARKET UKCOLIN  SHANNONEVP, Global Clinical Ops WILMINGTONWilliam J  SharbaughChief Operating Officer WILMINGTONWilliam J  SharbaughWILMINGTONRALPH  SNYDERMANDirector WILMINGTONW RICHARD  STAUBSr. Vice President RALEIGHMichael O.  WilkinsonWILMINGTONMichael O.  WilkinsonChief Information Officer WILMINGTONPeter J  WilkinsonVP of Fin./Chief Acctg. Off. WILMINGTONPeter J  WilkinsonVP of Fin./Chief Acctg. Off. WILMINGTONPersons related to FREDRIC N  ESHELMAN - MEDICINES CO /DENamePositionCityPaul Michael  AntinoriPARSIPPANYPaul Michael  AntinoriSVP and General Counsel PARSIPPANYPaul Michael  AntinoriSVP and General Counsel PARSIPPANYPaul Michael  AntinoriSr. VP & General Counsel PARSIPPANYLEONARD  BELLLEONARD  BELLDirector CHESHIREChristopher T  CoxEVP & Chief Corp. Dev. Officer CHELMSFORDWILLIAM  CROUSEDirector WILLIAM  CROUSEDirector PRINCETONWILLIAM  CROUSEDirector PARSIPPANYWILLIAM  CROUSEDirector PARSIPPANYWILLIAM  CROUSEDirector PARSIPPANYDEERFIELD CAPITAL LPNEW YORKDEERFIELD INTERNATIONAL LTDTORTOLAMANAGEMENT CO /NY  DEERFIELDNEW YORKDEERFIELD PARTNERS, LPNEW YORKAlexander J  DennerDirector GREENWICHFREDRIC N  ESHELMANDirector WILMINGTONJames E  Flynn10% Owner NEW YORKJeff  FrazierEVP, Chief Human Strategy PARSIPPANYBrent  FurseEVP, Chief Customer Officer PARSIPPANYCornelis  HeimanEVP, Chief Innovation Officer PARSIPPANYROBERT J  HUGINDirector ROBERT J  HUGINDirector PARSIPPANYROBERT J  HUGINDirector PARSIPPANYROBERT J  HUGINDirector PARSIPPANYROBERT J  HUGINDirector PARSIPPANYT SCOTT  JOHNSONT SCOTT  JOHNSONDirector PARSIPPANYT SCOTT  JOHNSONDirector PARSIPPANYT SCOTT  JOHNSONDirector PARSIPPANYT SCOTT  JOHNSONDirector PARSIPPANYT SCOTT  JOHNSONDirector PARSIPPANYT SCOTT  JOHNSONDirector PARSIPPANYJohn P  KelleyPresident and COO PARSIPPANYJohn C.  KellyDirector MADISONJohn C.  KellyDirector PARSIPPANYJohn C.  KellyPARSIPPANYARMIN M  KESSLERDirector ARMIN M  KESSLERDirector PARSIPPANYARMIN M  KESSLERDirector PARSIPPANYARMIN M  KESSLERDirector PARSIPPANYStuart A  KingsleyPresident and COO MARLBOROUGHSTEVEN H  KOEHLERSenior Vice President and CFO PARSIPPANYSTEVEN H  KOEHLERSenior Vice President and CFO PARSIPPANYVictoria  KusiakEVP, Chief Integrity Officer PARSIPPANYCLIVE  MEANWELLCEO CLIVE  MEANWELLChief Executive Officer PARSIPPANYCLIVE  MEANWELLChief Executive Officer PARSIPPANYCLIVE  MEANWELLChief Executive Officer PARSIPPANYCLIVE  MEANWELLChairman & CEO PARSIPPANYCatharine S  NewberrySenior Vice President PARSIPPANYWilliam Bernard  O'ConnorChief Financial Officer PARSIPPANYWilliam Bernard  O'ConnorSr VP & Chief Acct. Officer PARSIPPANYWilliam Bernard  O'ConnorChief Accounting Officer PARSIPPANYParis  PanayiotopoulosDirector CAMBRIDGEJOHN D  RICHARDSVice President PARSIPPANYJOHN D  RICHARDSVice President PARSIPPANYStephen M  RodinEVP and General Counsel PARSIPPANYLeslie C  RohrbackerVP, Chief Human Strategy Offic PARSIPPANYROBERT G  SAVAGEDirector Robert G.  SavageDirector PARSIPPANYRobert G.  SavageDirector PARSIPPANYRobert G.  SavageDirector PARSIPPANYROBERT G  SAVAGEDirector PARSIPPANYROBERT G  SAVAGEDirector PARSIPPANYGLENN  SBLENDORIOPresident & CFO NEW YORKGLENN  SBLENDORIOExecutive Vice President PARSIPPANYGLENN  SBLENDORIOExecutive Vice President PARSIPPANYGLENN  SBLENDORIOPresident & CFO PARSIPPANYHiroaki  ShigetaDirector PARSIPPANYHiroaki  ShigetaDirector PARSIPPANYMelvin K  SpigelmanDirector PARSIPPANYMelvin K  SpigelmanDirector PARSIPPANYDAVID M  STACKDAVID M  STACKPresident and Chief Executive PARSIPPANYPETER  TEUBERPETER  TEUBERVice President PARSIPPANYJAMES E  THOMASDirector Pacicco Kelli  WatsonSenior Vice President PARSIPPANYELIZABETH H S  WYATTDirector ELIZABETH H S  WYATTDirector PARSIPPANYELIZABETH H S  WYATTDirector PARSIPPANYPersons related to FREDRIC N  ESHELMAN - G1 Therapeutics, Inc.NamePositionCityWebb  CarolChapel HillWebb  CarolChapel HillWebb  CarolChapel HillWebb  CarolResearch Triangle ParkShaffer  ChristyChapel HillShaffer  ChristyChapel HillShaffer  ChristyResearch Triangle ParkBlack  ClaudiaChapel HillThorp  ClayChapel HillThorp  ClayChapel HillThorp  ClayResearch Triangle ParkJohn  CrumplerDURHAMFREDRIC N  ESHELMANDirector WILMINGTONEshelman Ventures, LLC10% Owner RESEARCH TRIANGLE PARKEshelman  FredericRESEARCH TRIANGLE PARKMuir  GlennRESEARCH TRIANGLE PARKMossinghoff  GregoryResearch Triangle ParkHatteras Venture Advisors IV SBIC, LLCDURHAMHatteras Venture Partners IV SBIC, LPDURHAMROBERT A  INGRAMStaun  JayChapel HillStrum  JayChapel HillStrum  JayChapel HillStrum  JayResearch Triangle ParkPeter  KolchinskyBOSTONWong  Kwok-KinArlingtonKENNETH B  LEE JRRajesh  MalikRESEARCH TRIANGLE PARKVelleca  MarkResearch Triangle ParkMedImmune Ventures, Inc.10% Owner GAITHERSBURGGutch  MichaelResearch Triangle ParkJennifer K.  MosesRESEARCH TRIANGLE PARKGREGORY J  MOSSINGHOFFDURHAMGLENN P  MUIRDirector Sharpless  NormanChapel HillSharpless  NormanChapel HillSharpless  NormanChapel HillSharpless  NormanResearch Triangle ParkKolchinsky  PeterRESEARCH TRIANGLE PARKRA Capital Biotech Fund LPBOSTONRA CAPITAL MANAGEMENT, LLC BOSTONDouglas MD  ReedDEERFIELDTyrell  RiversRESEARCH TRIANGLE PARKLaufer  RonResearch Triangle ParkSETH  RUDNICKDirector ROWAYTONRudnick  SethResearch Triangle ParkCHRISTY L  SHAFFERDirector Jay  StrumChief Scientific Officer RESEARCH TRIANGLE PARKTimothy Eugene  SullivanRESEARCH TRIANGLE PARKLaundon  ThomasChapel HillLaundon  ThomasChapel HillLaundon  ThomasResearch Triangle ParkClay  Thorp10% Owner DURHAMSullivan  TimothyRESEARCH TRIANGLE PARKMark A.  VellecaRESEARCH TRIANGLE PARKANDREW  WITTYDirector RESEARCH TRIANGLE PARK












 

















 





MDCO Fredric N. Eshelman Insider Trades for Medicines Co.


































Bulletin






Investor Alert







London Markets Open in:



Asia Markets
Currencies
US Market Snapshot


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Medicines Co.

                  NASDAQ: MDCO
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Medicines Co.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 4:33 p.m.


MDCO

/quotes/zigman/83890/composite


$
39.46




Change

-0.0079
-0.02%

Volume
Volume 6,750
Quotes are delayed by 20 min








/quotes/zigman/83890/composite
Previous close

$
			39.08
		


$
				39.47
			
Change

+0.39
+1.00%





Day low
Day high
$38.86
$39.67










52 week low
52 week high

            $30.80
        

            $55.95
        


















Insider Activity


Individual




Fredric N. Eshelman



Dr. Fredric N. Eshelman is a Director at Accelerator Corp. and Founder at Eshelman Ventures LLC. He is on the Board of Directors at The Medicines Co., Aton Pharma, Inc., G1 Therapeutics, Inc., Innocrin Pharmaceuticals, Inc., XORI Corp. and North Carolina School of Science & Mathematics. 
Dr. Eshelman was previously employed as a Principal by Boehringer Mannheim Pharmaceuticals Corp., Founding Chairman by Furiex Pharmaceuticals, Inc., Senior Vice President & Director by Glaxo, Inc., Chief Executive Officer & Executive Chairman by Pharmaceutical Product Development LLC, and a Trustee by University of North Carolina at Wilmington. 
He received his undergraduate degree from the University of North Carolina at Chapel Hill and a doctorate degree from the University of Cincinnati (Ohio).



Transactions


Date
Shares
Transaction
Value





05/25/2017
3,237


 
Award at $0 per share.


0


12/08/2016
5,501


 
Acquisition at $33.19 per share.


182,578


12/08/2016
19,188


 
Acquisition at $32.51 per share.


623,801


12/07/2016
86,587


 
Acquisition at $32.9 per share.


2,848,712


12/07/2016
172,764


 
Acquisition at $33.61 per share.


5,806,598


12/06/2016
337,680


 
Acquisition at $34.15 per share.


11,531,772


05/26/2016
3,426


 
Award at $0 per share.


0


05/12/2016
300,000


 
Acquisition at $33.68 per share.


10,104,000





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Fredric N. Eshelman 
Non-Executive Chairman




Mr. Stuart Anthony Kingsley 
President & Chief Operating Officer




Dr. Clive A. Meanwell 
Chief Executive Officer & Director




Mr. William Bernard O'Connor 
SVP, Chief Financial & Accounting Officer




Dr. David  Kallend 
Vice President & Global Medical Director




Mr. Christopher T. Cox 
Chief Corporate Development Officer & EVP




Mr. Gregory  Moeck 
Head-Infectious Disease Biology




Dr. Michael N. Dudley 
Senior Vice President & Head-Health Science




Mr. Robert  Werner 
Vice President-Value & Market Access




Ms. Tanya  Quinn 
Senior Director-Global Distribution




Dr. Stephanie  Plent 
EVP & Head-Global Health Economics




Dr. John W. Villiger 
Executive Vice President




Dr. Bruce R. Rosengard 
Vice President-New Business Ventures




Mr. Jeffrey A. Frazier 
Chief Human Strategy Officer & Executive VP




Mr. Mike  McGuire 
Infectious Disease Pathway Leader




Mr. Ray  Russo 
Vice President-Global Chest Pain Pathway




Mr. Anthony  Flammia 
Vice President & GM-Mergers & Acquisitions




Mr. Paris  Panayiotopoulos 
Director




Ms. Margaret  Langan 
Vice President-Media Relations




Dr. Krishna  Gorti 
Vice President-Investor Relations




Dr. Nancye  Green 
Executive Vice President-Global Communications




Mr. Bob  Laverty 
Vice President-Communications




Mr. Stephen M. Rodin 
Secretary, Senior Vice President & General Counsel




Dr. Loretta M. Itri 
EVP-Global Health Science & Regulatory Affairs




Dr. Alexander John Denner 
Independent Director




Mr. William W. Crouse 
Independent Director




Mr. Armin M. Kessler 
Independent Director




Dr. Elizabeth Hamilton Seabury Wyatt 
Lead Independent Director




Dr. Melvin K. Spigelman 
Independent Director




Mr. John C. Kelly 
Independent Director




Mr. Robert J. Hugin 
Independent Director




Mr. Hiroaki  Shigeta 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/65801738/composite TLT+1.11%


/quotes/zigman/59386294/composite JNUG-5.94%


X




Powered by














Log In




2:48 AM EDT
July 24, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
2:46aTrump to make statement on healthcare Monday: reports
2:28aReckitt Benckiser profit rises on reduced costs
2:15aChinese regulator tells insurers to shape up
2:14aRandgold looks to get more out of Tongon mine
2:12aRyanair profit soars 55%; warns on overcapacity
2:10aSiemens and Bombardier in talks to form train JVs
2:09aVW asks EU to scrutinize German car makers
2:04aKKR close to announcing deal for WebMD
1:45aJulius Baer assets under management jump
1:44aRoyal Philips profit rises, begins share buybacks
1:44aRyanair profit rises 55%, beating expectations
1:34aHow OPEC committee’s coming meeting could make or break oil prices
1:32aOil prices steady with all eyes on OPEC meeting
1:13aJapan, Aussie stocks knocked by weak dollar, commodity prices
12:53aIMF cuts U.S. growth forecast for 2017, 2018
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































Insider trading history of Eshelman Fredric N    at G1 Therapeutics, Inc. 



















Insider Monitor



Realtime

Insider Buys 

Insider buys today     
Insider buys 1 day ago
Insider buys 2 days ago
Insider buys 3 days ago
Insider buys 4 days ago
Insider buys 5 days ago
Insider buys 6 days ago
Insider buys 7 days ago
Insider buys 8 days ago
Insider buys 9 days ago
Insider buys 10 days ago



Insider Sales 

Insider sales today       
Insider sales 1 day ago
Insider sales 2 days ago
Insider sales 3 days ago
Insider sales 4 days ago
Insider sales 5 days ago
Insider sales 6 days ago
Insider sales 7 days ago



Top 10 

Top 10 insider buys of the week
Top 10 officer buys of the week
Top 10 insider buys of the month
Top 10 officer buys of the month
Top 10 insider sales of the week
Top 10 insider sales of the month









               
		







 Insider Stock Trading History of Eshelman Fredric N  








The following table details the trading activities 
(stock purchases, stock sales, and stock option exercises) 
reported to 
the Securities and Exchange Commission (SEC) 
by insider Eshelman Fredric N  since year 2005. 
The trader's CIK number is 1033409.
At the time of this reporting, Eshelman Fredric N  is the Director of G1 Therapeutics, Inc. . 
(stock ticker symbol GTHX).
See this page for all insider trading activities at G1 Therapeutics, Inc. . 


Note that in the past ESHELMAN FREDRIC N also reported insider trading activities as an insider of the following companies:
 Insider Activities at G1 Therapeutics, Inc.  (GTHX)
 Insider Activities at Medicines Co /de  (MDCO)
 Insider Activities at Furiex Pharmaceuticals, Inc.  (FURX)
 Insider Activities at Pharmaceutical Product Development Inc  (PPDI)




Stock purchases, sales, and option exercises reported by insider Eshelman Fredric N  since 2005.
  

   Trade Date   
 Symbol 
 Company Name (Issuer) 
 Trade Type 
     Shares   
     Price ($)
   Value ($) 

 2017-05-22  GTHX  G1 Therapeutics, Inc.   Buy  300,000  15.00  4,500,000 
 2016-12-06  MDCO  Medicines Co /de   Buy  337,680  34.15  11,531,772 
 2016-12-07  MDCO  Medicines Co /de   Buy  259,351  33.26  8,624,717 
 2016-12-08  MDCO  Medicines Co /de   Buy  24,689  32.85  811,033 
 2016-05-12  MDCO  Medicines Co /de   Buy  300,000  33.68  10,104,000 
 2012-06-21  FURX  Furiex Pharmaceuticals, Inc.   Option Ex  65,875  9.11  600,121 
 2012-06-13  FURX  Furiex Pharmaceuticals, Inc.   Buy  44,193  18.33  810,057 
 2012-06-14  FURX  Furiex Pharmaceuticals, Inc.   Buy  34,133  19.04  649,892 
 2012-05-31  FURX  Furiex Pharmaceuticals, Inc.   Buy  70,075  20.06  1,405,704 
 2012-06-01  FURX  Furiex Pharmaceuticals, Inc.   Buy  50,319  19.72  992,290 
 2012-05-29  FURX  Furiex Pharmaceuticals, Inc.   Buy  72,431  19.96  1,445,722 
 2012-05-30  FURX  Furiex Pharmaceuticals, Inc.   Buy  96,321  19.87  1,913,898 
 2012-05-25  FURX  Furiex Pharmaceuticals, Inc.   Buy  1,454  18.45  26,826 
 2012-05-24  FURX  Furiex Pharmaceuticals, Inc.   Buy  27,000  17.99  485,729 
 2012-05-22  FURX  Furiex Pharmaceuticals, Inc.   Buy  35,000  16.93  592,550 
 2012-05-23  FURX  Furiex Pharmaceuticals, Inc.   Buy  20,000  17.73  354,600 
 2012-05-21  FURX  Furiex Pharmaceuticals, Inc.   Buy  2,400  16.15  38,760 
 2012-05-18  FURX  Furiex Pharmaceuticals, Inc.   Buy  25,000  15.28  382,000 
 2012-03-15  FURX  Furiex Pharmaceuticals, Inc.   Buy  7,102  23.91  169,808 
 2012-03-13  FURX  Furiex Pharmaceuticals, Inc.   Buy  22,594  23.45  529,829 
 2012-03-14  FURX  Furiex Pharmaceuticals, Inc.   Buy  22,713  23.75  539,433 
 2012-03-08  FURX  Furiex Pharmaceuticals, Inc.   Buy  14,914  22.52  335,863 
 2012-03-09  FURX  Furiex Pharmaceuticals, Inc.   Buy  15,237  22.59  344,203 
 2012-03-12  FURX  Furiex Pharmaceuticals, Inc.   Buy  22,351  22.69  507,144 
 2012-03-06  FURX  Furiex Pharmaceuticals, Inc.   Buy  15,237  20.87  317,996 
 2012-03-05  FURX  Furiex Pharmaceuticals, Inc.   Buy  15,237  20.55  313,120 
 2011-12-20  FURX  Furiex Pharmaceuticals, Inc.   Option Ex  65,876  9.11  600,130 
 2011-12-15  FURX  Furiex Pharmaceuticals, Inc.   Buy  17,359  16.88  293,019 
 2011-12-13  FURX  Furiex Pharmaceuticals, Inc.   Buy  94,611  17.00  1,608,387 
 2011-12-14  FURX  Furiex Pharmaceuticals, Inc.   Buy  20,056  16.70  334,935 
 2011-12-05  FURX  Furiex Pharmaceuticals, Inc.   Buy  110,664  17.65  1,953,219 
 2011-12-02  FURX  Furiex Pharmaceuticals, Inc.   Buy  27,652  17.50  483,910 
 2011-12-01  FURX  Furiex Pharmaceuticals, Inc.   Buy  25,026  17.60  440,457 
 2011-11-25  FURX  Furiex Pharmaceuticals, Inc.   Buy  6,802  16.00  108,832 
 2011-11-23  FURX  Furiex Pharmaceuticals, Inc.   Buy  15,278  16.22  247,809 
 2011-11-18  FURX  Furiex Pharmaceuticals, Inc.   Buy  23,625  15.87  374,928 
 2011-11-21  FURX  Furiex Pharmaceuticals, Inc.   Buy  12,468  15.48  193,004 
 2011-11-10  FURX  Furiex Pharmaceuticals, Inc.   Buy  12,889  16.48  212,410 
 2011-11-09  FURX  Furiex Pharmaceuticals, Inc.   Buy  947  16.26  15,398 
 2011-11-04  FURX  Furiex Pharmaceuticals, Inc.   Buy  6,922  15.33  106,114 
 2011-11-07  FURX  Furiex Pharmaceuticals, Inc.   Buy  7,148  15.69  112,152 
 2011-11-08  FURX  Furiex Pharmaceuticals, Inc.   Buy  250,000  16.00  4,000,000 
 2011-05-24  FURX  Furiex Pharmaceuticals, Inc.   Buy  14,516  14.79  214,691 
 2011-05-25  FURX  Furiex Pharmaceuticals, Inc.   Buy  250,000  15.35  3,837,500 
 2011-05-18  FURX  Furiex Pharmaceuticals, Inc.   Buy  12,599  14.52  182,937 
 2011-05-19  FURX  Furiex Pharmaceuticals, Inc.   Buy  12,599  14.12  177,897 
 2011-05-20  FURX  Furiex Pharmaceuticals, Inc.   Buy  465,000  13.99  6,505,350 
 2008-05-19  PPDI  Pharmaceutical Product Development Inc   Sale  40,000  43.00  1,719,840 
 2008-05-20  PPDI  Pharmaceutical Product Development Inc   Sale  30,780  42.57  1,310,396 
 2008-05-20  PPDI  Pharmaceutical Product Development Inc   Sale  65,220  42.72  2,786,002 
 2008-05-21  PPDI  Pharmaceutical Product Development Inc   Sale  14,000  43.56  609,854 
 2007-07-16  PPDI  Pharmaceutical Product Development Inc   Sale  4,004  39.03  156,288 
 2007-07-16  PPDI  Pharmaceutical Product Development Inc   Sale  41,496  38.84  1,611,497 
 2007-07-16  PPDI  Pharmaceutical Product Development Inc   Sale  21,400  38.52  824,306 
 2007-07-16  PPDI  Pharmaceutical Product Development Inc   Sale  16,434  38.21  627,943 
 2007-07-02  PPDI  Pharmaceutical Product Development Inc   Sale  47,900  38.17  1,828,534 
 2007-07-02  PPDI  Pharmaceutical Product Development Inc   Sale  35,433  38.44  1,362,079 
 2007-06-18  PPDI  Pharmaceutical Product Development Inc   Sale  27,852  36.98  1,029,966 
 2007-06-18  PPDI  Pharmaceutical Product Development Inc   Sale  55,382  36.71  2,033,017 
 2007-06-19  PPDI  Pharmaceutical Product Development Inc   Sale  100  36.58  3,658 
 2007-06-01  PPDI  Pharmaceutical Product Development Inc   Sale  61,792  36.74  2,270,052 
 2007-06-01  PPDI  Pharmaceutical Product Development Inc   Sale  21,341  37.07  791,068 
 2007-06-01  PPDI  Pharmaceutical Product Development Inc   Sale  200  37.27  7,454 
 2007-05-14  PPDI  Pharmaceutical Product Development Inc   Sale  74,334  33.62  2,499,480 
 2007-05-14  PPDI  Pharmaceutical Product Development Inc   Sale  9,000  33.91  305,189 
 2007-05-01  PPDI  Pharmaceutical Product Development Inc   Sale  900  35.45  31,908 
 2007-05-01  PPDI  Pharmaceutical Product Development Inc   Sale  63,433  35.17  2,231,255 
 2007-05-01  PPDI  Pharmaceutical Product Development Inc   Sale  19,000  34.85  662,093 
 2007-04-16  PPDI  Pharmaceutical Product Development Inc   Sale  34,800  34.52  1,201,365 
 2007-04-16  PPDI  Pharmaceutical Product Development Inc   Sale  24,733  34.80  860,609 
 2007-04-16  PPDI  Pharmaceutical Product Development Inc   Sale  23,800  34.20  814,055 
 2007-04-02  PPDI  Pharmaceutical Product Development Inc   Sale  83,333  33.59  2,798,988 
 2007-03-19  PPDI  Pharmaceutical Product Development Inc   Sale  83,034  31.64  2,627,112 
 2007-03-19  PPDI  Pharmaceutical Product Development Inc   Sale  300  31.80  9,541 
 2007-03-01  PPDI  Pharmaceutical Product Development Inc   Sale  52,133  31.26  1,629,781 
 2007-03-01  PPDI  Pharmaceutical Product Development Inc   Sale  31,200  31.48  982,020 
 2007-02-26  PPDI  Pharmaceutical Product Development Inc   Sale  33,000  33.13  1,093,224 
 2007-02-26  PPDI  Pharmaceutical Product Development Inc   Sale  6,800  33.48  227,684 
 2007-02-26  PPDI  Pharmaceutical Product Development Inc   Sale  43,533  32.80  1,427,664 
 2007-02-20  PPDI  Pharmaceutical Product Development Inc   Sale  25,133  33.55  843,337 
 2007-02-20  PPDI  Pharmaceutical Product Development Inc   Sale  58,200  33.34  1,940,097 
 2006-05-15  PPDI  Pharmaceutical Product Development Inc   Sale  54,575  36.95  2,016,709 
 2006-05-15  PPDI  Pharmaceutical Product Development Inc   Sale  198,425  36.69  7,279,419 
 2006-05-16  PPDI  Pharmaceutical Product Development Inc   Sale  12,180  36.76  447,675 
 2006-05-16  PPDI  Pharmaceutical Product Development Inc   Sale  62,775  36.53  2,293,421 
 2006-05-16  PPDI  Pharmaceutical Product Development Inc   Sale  72,045  36.22  2,609,109 
 2005-07-22  PPDI  Pharmaceutical Product Development Inc   Sale  54,601  59.72  3,260,607 
 2005-07-22  PPDI  Pharmaceutical Product Development Inc   Sale  17,947  59.75  1,072,333 
 2005-07-21  PPDI  Pharmaceutical Product Development Inc   Sale  209,989  59.96  12,590,310 
 2005-07-21  PPDI  Pharmaceutical Product Development Inc   Sale  77,788  59.81  4,652,733 
 2005-07-21  PPDI  Pharmaceutical Product Development Inc   Sale  39,675  59.65  2,366,732 


Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more  information regarding the trades made by Eshelman Fredric N  
(Director of G1 Therapeutics, Inc.  at the time of this reporting) see 

the Securities and Exchange Commission (SEC)  website.


















 



















Newest Insider Buys 
Insider Trading Resources 
Archive  
Privacy  
Contact  
2016,2017 Market Holidays 
Market Hours 






Tweet



 ©2017, insider-monitor.com. All rights reserved. 
 













 



Dr. Fredric N. Eshelman Files Preliminary Written Consent Statement in Connection with Puma Biotechnology Inc. | Business Wire


























































Dr. Fredric N. Eshelman Files Preliminary Written Consent Statement 
      in Connection with Puma Biotechnology Inc.






October 28, 2015 07:00 PM Eastern Daylight Time



NEW YORK--(BUSINESS WIRE)--Dr. Fredric N. Eshelman today filed a Preliminary Consent Statement with 
      the Securities and Exchange Commission in connection with his proposed 
      solicitation of written consents from the holders of shares of common 
      stock of Puma Biotechnology, Inc.
    

      Dr. Eshelman is the beneficial owner of approximately 1 percent of the 
      issued and outstanding shares of Puma common stock.
    

      Dr. Eshelman’s Preliminary Consent Statement includes proposals to 
      increase the size of the board of directors of Puma from five to nine 
      directors and to elect as new directors Dr. Eshelman and three other 
      highly qualified candidates: James M. Daly, Seth A. Rudnick, M.D., and 
      Kenneth B. Lee, Jr.
    

      Dr. Eshelman has more than 35 years of strategic development, executive, 
      operational and financial leadership experience in the pharmaceutical 
      and healthcare industries. He is currently Non-Executive Chairman of The 
      Medicines Company, and previously founded Pharmaceutical Product 
      Development, Inc. (“PPD”) and Furiex Pharmaceuticals, Inc. (“Furiex”). 
      In 2014, Dr. Eshelman founded Eshelman Ventures, LLC, an investment 
      company focused on healthcare companies. Dr. Eshelman also serves on the 
      boards of directors of several privately held companies, including 
      AeroMD, Cellective Biotherapy, Inc., Dignify Therapeutic, Inc., 
      Eyenovia, Inc., G1 Therapeutics, Inc., Innocrin Pharmaceuticals, Inc., 
      Medikidz USA, Inc., Meryx, Inc. and Neoantigenics LLC, and on the 
      advisory board of Auven Therapeutics.
    

      James M. Daly served as Executive Vice President and Chief Commercial 
      Officer at Incyte Corporation, a biopharmaceutical company, from October 
      2012 until June 2015, and has served as a director of Chimerix Inc., a 
      privately held biotechnology company, since 2014. Prior to joining 
      Incyte, Mr. Daly served as Senior Vice President of North America 
      Commercial Operations and Global Marketing/Commercial Development at 
      Amgen Inc., a global pharmaceutical company. Prior to his employment 
      with Amgen, Mr. Daly was Senior Vice President and General Manager of 
      the Respiratory/Anti-infective business unit at GlaxoSmithKline.
    

      Seth A. Rudnick, M.D., is currently Chairman of several privately held 
      biotechnology companies, including Meryx Pharmaceuticals, Liquidia 
      Technologies, Inc., and G1 Therapeutics. Dr. Rudnick also serves on the 
      Board of Square 1, a public company. Previously, Dr. Rudnick was the 
      Chief Executive Officer and Chairman of CytoTherapeutics Inc., a company 
      developing stem cell-based therapies. In addition, he helped found and 
      served as the Head of Research and Development for Ortho Biotech, a 
      division of Johnson & Johnson focusing on cancer and chronic illnesses. 
      Dr. Rudnick is a Clinical Adjunct Professor of Medicine at University of 
      North Carolina, Chapel Hill.
    

      Kenneth B. Lee, Jr., is a managing member of Hatteras BioCapital, LLC 
      and the general partner of Hatteras BioCapital Fund, L.P., a venture 
      capital fund focusing on life sciences companies. Currently, Mr. Lee 
      serves on the boards of directors of the following publicly held 
      companies: Biocryst Pharmaceuticals, Inc. and Pozen Inc., for which he 
      serves as Lead Director, Chairman of the compensation committee and as a 
      member of the audit committee. Mr. Lee also serves on the Board of two 
      private companies, Clinverse, Inc., and Clinipace Worldwide Inc., for 
      which he serves as Chairman, and is a co-founder of the National 
      Conference on Biotechnology Venture. Between 2002 and 2013, Mr. Lee 
      served on the boards of directors of several public companies: Maxygen, 
      Inc., OSI Pharmaceuticals, Inc., CV Therapeutics, Inc., Abgenix, Inc., 
      and Inspire Pharmaceuticals, Inc. Mr. Lee was formerly national director 
      of the life science practice at Ernst and Young LLP where he advised 
      biotechnology and pharmaceutical companies throughout the world on a 
      wide range of financial and strategic planning issues. Mr. Lee received 
      a B.A. from Lenoir-Rhyne College and an M.B.A. from the University of 
      North Carolina at Chapel Hill.
    

      The proposals contained in the consent statement will be effective 
      without further action by Puma or its board when Dr. Eshelman delivers 
      to the Company written consents from the holders of a majority of the 
      outstanding shares of Puma common stock.
    

      Dr. Eshelman has retained Cadwalader, Wickersham & Taft LLP and Young 
      Conaway Stargatt & Taylor, LLP as legal counsel on this matter.
    

      THIS PRESS RELEASE IS NOT A PROXY STATEMENT OR A CONSENT STATEMENT, NOR 
      IS IT A SOLICITATION OF ANY PROXY OR CONSENT. ANY SUCH SOLICITATION WILL 
      BE MADE ONLY BY A WRITTEN DEFINITIVE CONSENT SOLICITATION STATEMENT (THE 
      "DEFINITIVE CONSENT STATEMENT"), DULY FILED WITH THE SEC. DR. ESHELMAN 
      AND THE NOMINEES HAVE FILED A PRELIMINARY CONSENT STATEMENT (THE 
      "PRELIMINARY CONSENT STATEMENT") WITH THE SEC. PLEASE READ THE 
      PRELIMINARY CONSENT STATEMENT CAREFULLY BECAUSE IT CONTAINS IMPORTANT 
      INFORMATION ABOUT THE IDENTITY OF THE PARTICIPANTS, INCLUDING, BUT NOT 
      LIMITED TO, DR. ESHELMAN, THE PROPOSALS HE IS ASKING THE STOCKHOLDERS TO 
      APPROVE, THE NOMINEES THAT HE IS PROPOSING TO BE ELECTED TO SERVE ON THE 
      COMPANY'S BOARD OF DIRECTORS AND THEIR RESPECTIVE HOLDINGS (SECURITIES 
      OR OTHERWISE, DIRECT OR INDIRECT) IN THE COMPANY. YOU MAY OBTAIN A FREE 
      COPY OF THE PRELIMINARY CONSENT STATEMENT AND, WHEN AVAILABLE, THE 
      DEFINITIVE CONSENT STATEMENT, AT THE SEC'S WEBSITE (WWW.SEC.GOV) 
      OR BY DIRECTING A REQUEST TO OKAPI PARTNERS LLC AT THE INVESTOR 
      INQUIRIES CONTACT ABOVE.
    

      Certain Information Regarding Forward-Looking Statements
    

      This press release includes forward-looking statements within the 
      meaning of Section 27A of the Securities Act of 1933, as amended, and 
      Section 21E of the Securities Exchange Act of 1934, as amended, 
      regarding, among other things, Dr. Eshelman plans to distribute a 
      definitive consent statement. Such forward-looking statements involve 
      known and unknown risks, uncertainties and other factors that may cause 
      actual results, performance or achievements to be materially different 
      from any future results, performance or achievements expressed or 
      implied by such forward-looking statements. Readers are cautioned not to 
      place undue reliance on these forward-looking statements, which speak 
      only as of the date thereof. We undertake no obligation to publicly 
      release the result of any revisions to these forward-looking statements 
      that may be made to reflect events or circumstances after the date 
      hereof or to reflect the occurrence of unanticipated events.
    




Contacts

Investors:Okapi Partners LLCBruce 
      Goldfarb, 877-869-0171bhgoldfarb@okapipartners.comorMedia:FinsburyKal 
      Goldberg / Chuck Nathan / Chris Ryall646-805-2000kal.goldberg@finsbury.comcharles.nathan@finsbury.comchris.ryall@finsbury.com















Contacts

Investors:Okapi Partners LLCBruce 
      Goldfarb, 877-869-0171bhgoldfarb@okapipartners.comorMedia:FinsburyKal 
      Goldberg / Chuck Nathan / Chris Ryall646-805-2000kal.goldberg@finsbury.comcharles.nathan@finsbury.comchris.ryall@finsbury.com









 
 

 






Search




Advanced News Search

Advanced News Search













Log In
Sign Up






















Eshelman Fredric N - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1033409 - Address: C/o G1 Therapeutics, Inc., 79 T.W. Alexander Drive, Research Triangle Park, NC 27709 70 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


P%ret211324412605P%wins858358806775 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



5/24/17 20:055/22/17GTHXG1 Therapeutics, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d4,50015.000300103,439I
12/8/16 16:5312/6/16MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsEshelman Fredric NNJDP.m20,99333.7733622501,870D24-17-13-11-8-13-80611960
5/13/16 17:045/12/16MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsEshelman Fredric NNJDP10,10433.6830300321,245D3130-17166-5-6-657891
6/22/12 16:156/21/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTM.d6009.1106622,841I
6/15/12 16:296/13/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm1,46018.6407832,775D
6/4/12 16:215/31/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm2,39819.92012052,697D
5/31/12 17:015/29/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm3,36019.91016972,576D
5/29/12 16:375/25/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d2718.450102,408D
5/25/12 16:365/24/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d48617.9902712,406D
5/24/12 16:185/22/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm94717.2205522,379D
5/22/12 16:585/21/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d3916.150202,324D
5/21/12 16:595/18/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d38215.2802512,322D
3/19/12 17:523/15/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d17023.910702,297D
3/15/12 17:303/13/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm1,06923.6024522,290D3549244031257
3/15/12 17:273/7/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.a1,63121.7527542,136D3549244031257
3/12/12 18:513/8/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm1,18722.6125322,169D3549244031257
3/7/12 17:173/5/12FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm63120.7113012,117D2546223026186-1
12/22/11 14:5312/20/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTM.d6009.1116632,086I24-2236-223-2-6-6
12/19/11 15:0912/15/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d29316.8811712,020D23-288-2-8300-4
12/15/11 16:4012/13/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm1,94316.95111562,003D30-68206-5203-3
12/5/11 16:5312/1/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm2,87817.62116391,888D35-620252422-8-1018
11/28/11 16:4911/23/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm35716.1522211,725D22-83161-81-12-46
11/22/11 11:3511/18/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm56815.7423621,703D26251612-6-6791115
11/14/11 15:5311/10/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d21216.4811311,667D4416129121961-8-4-1
11/10/11 15:4411/9/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.d1516.261101,654D357911201442234
11/8/11 16:2811/4/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDTP.dm4,21815.971264191,653D35646141214171410
5/26/11 17:005/24/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDP.dm4,05215.322265241,389D323-171116164-10-2
5/20/11 16:315/18/11FURXFuriex Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsEshelman Fredric NNCDP.dm6,86614.011490771,124D19-13-16-6-9-512123618
5/21/08 12:475/20/08PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.dm-3,39642.860-79-18,005D
5/21/08 12:465/19/08PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.dm-3,03142.820-71-18,084D
7/17/07 14:497/16/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-15639.020-408,351D
7/17/07 14:487/16/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-1,61238.840-4108,355D
7/17/07 14:477/16/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-82538.540-2108,396D
7/17/07 14:467/16/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-62838.200-1608,418D
7/3/07 13:247/2/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-1,36238.430-3508,434D
7/3/07 13:247/2/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-1,83138.230-48-18,469D
6/19/07 15:056/18/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-1,02836.920-2808,517D
6/19/07 15:046/18/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.dm-2,04136.780-55-18,545D
6/5/07 11:546/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-737.270-008,601D
6/5/07 11:536/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-78936.990-2108,601D
6/5/07 11:526/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-2,27336.790-62-18,622D
5/15/07 12:105/14/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-30533.910-908,684D
5/15/07 12:095/14/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-2,49833.600-74-18,693D
5/2/07 14:285/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-3235.520-108,767D
5/2/07 14:275/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-2,23035.150-63-18,768D
5/2/07 14:265/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-66334.900-1908,832D
4/18/07 12:494/16/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-86034.780-2508,851D
4/18/07 12:484/16/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-1,20334.570-3508,875D
4/18/07 12:464/16/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-81334.180-2408,910D
4/3/07 10:494/2/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-2,80033.590-83-18,934D
3/20/07 10:383/19/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-1031.800-009,017D
3/20/07 10:373/19/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-2,63031.670-83-19,018D
3/5/07 09:183/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-98131.460-3109,101D
3/5/07 09:183/1/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-1,63431.340-52-19,132D
2/27/07 17:092/26/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-22733.410-709,184D
2/27/07 17:092/26/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-1,09333.120-3309,191D
2/27/07 17:072/26/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-1,42832.810-4409,224D
2/21/07 14:062/20/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-84333.530-2509,267D
2/21/07 14:052/20/07PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-1,94233.370-58-19,292D
5/17/06 16:515/16/06PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-44736.740-1209,431D
5/17/06 16:495/16/06PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-2,29336.530-63-19,443D
5/17/06 16:485/16/06PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.d-2,60836.200-72-19,505D
5/17/06 15:465/15/06PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-2,01636.940-55-19,578D
5/17/06 15:435/15/06PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCOCEOS.d-7,27836.680-198-29,632D
7/25/05 14:247/22/05PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-1,07760.000-1804,962D
7/25/05 14:227/22/05PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-3,25059.530-55-14,980D
7/22/05 16:287/21/05PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-2,36759.650-40-15,035D
7/22/05 16:277/21/05PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS-4,65559.840-78-25,074D
7/22/05 16:257/20/05PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOS.m-12,58759.940-210-45,152D
5/27/05 08:345/26/05PPDIPharmaceutical Product Development IncNCHealthBiolabCommercial Physical & BiologiEshelman Fredric NNCDOCEOM.d5,70715.02038085,362D



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.









About Us | Eshelman Ventures LLC of Wilmington NC





























Eshelman Ventures, LLC







Toggle navigation




Eshelman Ventures, LLC



About Us
Investment Criteria
Portfolio
Press
Contact













 

About Us  	Fred Eshelman is the founder of Eshelman Ventures LLC, an investment company primarily interested in private healthcare companies. He often serves on the boards of portfolio companies. Previously he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests.	After PPD he served as Founding Chairman and largest shareholder of Furiex Pharmaceuticals (FURX, NASDAQ), a company which licensed and rapidly developed new medicines. Furiex was sold to Forest Labs/Actavis in July, 2014.	He is Chairman of The Medicines Company (MDCO, NASDAQ), and recently joined the board of Valeant Pharmaceuticals (VRX).	His career has also included positions as senior vice president (development) and board member of the former Glaxo, Inc., as well as various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals.	Eshelman has served on the executive committee of the Medical Foundation of North Carolina, was on the Board of Trustees for UNC-W and in 2011 was appointed by the NC General Assembly to serve on the Board of Governors for the state's multi-campus university system as well as the NC Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at UNC-CH, which was recently named the number one pharmacy school in the US. In May 2008 the school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.	Eshelman has received many awards including the Davie and Distinguished Service Awards from UNC and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, as well as the NC Entrepreneur Hall of Fame Award and the NC business hall of fame. He received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital and a BS in pharmacy from UNC-CH. He completed the OPM program at Harvard Business School.

 








Quick Links

Home
About Us
Investment Criteria
Portfolio
Press
Contact



Address
319 N. 3rd Street, Suite 301, Wilmington, NC 28401


Phone
(910) 558-6885
(910) 558-6885




Copyright © 2017 Eshelman Ventures, LLC. All Rights Reserved.Web Design & Hosting by Wilmington Design Co.









Fredric N Eshelman - Wilmington, NC | Intelius



























Sign In



We found Fredric N Eshelman in Wilmington, NC


Fredric N Eshelman

                                                                           Intelius found that Fredric N Eshelman  is  a male between 60 and 70 years old from Wilmington, NC.  We have connected them to
                17 addresses,
                8 phones,
                and 4 relatives or associates.
         





Also Known As

Fred Neville Eshelman


Get Report Now

Age

Fredric N Eshelman is in his 60s

Fredric Has Lived In

Wilmington, NC
Wrightsville Beach, NC
Morrisville, NC

Fredric's Relatives

Donna Clements
Robert Eshelman
Kimberly Eshelman
April Eshelman







Fredric N Eshelman



Zodiac SignCancer



GenderMale



Professional Status
Executive Chairman at PPD Inc



Get Report Now










Want to know more about Fredric? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Fredric, or use our people search engine to find others.
Get Background Check on Fredric N Eshelman
Get a Criminal Check on Fredric N Eshelman
Get a Public Record Report on Fredric N Eshelman
Get a People Search Report on Fredric N Eshelman


Fredric N Eshelman's Contact Information
Known Cities Lived In
Find out where Fredric N Eshelman has lived as well as Fredric N Eshelman's phone numbers and email addresses.




Fredric N Eshelman Has Lived in 1 States
North Carolina Address for Fredric N Eshelman


6799 T***** R* 

Wilmington, NC


Has Lived In

Wilmington, NC
Wrightsville Beach, NC


Get Full Address Report










Phone Numbers Associated with Fredric N Eshelman

(910) ***-**** - Wilmington, NC 
(910) ***-**** - Wilmington, NC 
(919) ***-**** - Morrisville, NC 


Get Full Phone Report



Email Addresses Associated with Fredric N Eshelman

f**d@***.com
f***********n@***.com
f****************n@***.com


Get Email Report




Fredric N Eshelman's Education Information
Known Schools Attended
Learn about Fredric N Eshelman's academic history.  Find out which schools Fredric N Eshelman attended, the dates attended as well as the degrees Fredric N Eshelman received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Fredric N Eshelman Has Attended 2 Schools
University of North Carolina at Chapel Hill Fredric N Eshelman has a Bachelor's degree in Pharmacy               
Central High School               1962 – 1966                              


Fredric N Eshelman's Professional Information
Information regarding Fredric N Eshelman's professional history.  Find out previous places Fredric N Eshelman has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Fredric N Eshelman Has Worked at 13 Places
Company: PPD Inc
               Title: Executive Chairman
Company: PPD Inc
               Title: Chief Executive Officer
Fredric N Eshelman's Experience
Title: Executive Chairman
               Company: PPD Inc
Job Details
               Company Size: $500 mil to less than $1 bil - Employee Range: 25 to less than 100. PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
Title: Chief Executive Officer
               Company: PPD Inc
Job Details
               Company Size: $5 mil to less than $10 mil - Employee Range: 25 to less than 100. PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
Additional Professional Information on Fredric N Eshelman

 See Fredric N Eshelman's LinkedIn Profile



Fredric N Eshelman's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Fredric N Eshelman


Fredric N Eshelman's known Social Networks And Potential Email Matches

Find all of Fredric N Eshelman's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Fredric Eshelman
Username Matches

                  FredricEshelman
                  EshelmanFredric
                  Fredric.Eshelman
                  Eshelman.Fredric
                  Fredric_Eshelman
                  Eshelman_Fredric
                  Fredric-Eshelman
                  Eshelman-Fredric
                  FEshelman
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
F Eshelman







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











